Search

1 Jul 2024: OutSee. OutSee. DISCOVERING NOVEL DRUG TARGETS USINGAN INNOVATIVE AI GENOMICS TECHNOLOGYTHAT UNCOVERS DISEASE-MODULATINGBIOLOGICAL MECHANISMS. Website. Overview. OutSee is being launched to take advantage of the opportunity to exploit large-scale

1 Jul 2024: 360 implant to treat spinal cord injuries. BACKGROUND. The spinal cord is a key organ of the nervous system, which is in charge of carryinginformation around the body. Every year between 250,000-500,000 people sufferinjuries to the spinal cord

1 Jul 2024: MutREAD – Mutational Signature Detection byRestriction Enzyme-Associated DNA Sequencing. BACKGROUND. The successful application of mutational signatures in clinical settingsrequires availability of a cost-effective, scalable detection method that

1 Jul 2024: PredictImmune. PredictImmune. HELPING PATIENTS DIAGNOSED WITHCHRONIC IMMUNE-MEDIATED DISORDERS TOLIVE NORMAL AND HEALTHY LIVES. Website. Overview. PredictImmune developes prognostic assays that predict disease progression forpatients with

1 Jul 2024: Real-time autofocus for videomicroscopy. BACKGROUND. Video-microscopy of living subjects is hampered by their movement out of themicroscope’s focal plane. At video frame-rates, manual refocusing becomesimpossible; therefore, autofocus is required.

1 Jul 2024: Neonatal wireless transmission system. BACKGROUND. When babies are in intensive care, they need to be continuously monitored. Thisrequires multiple sensors with separate wires. These wires can become tangledand make clinical care harder. Parents

1 Jul 2024: Low-Cost Trace Analyte Detection with ReusableSERS Substrates. BACKGROUND. To move beyond current low-cost sensors, towards measuring trace analytes inapplications such as healthcare monitoring, geology and mineralogy, pollutionmonitoring, and

1 Jul 2024: Mouse Models of Essential Thrombocythemia(ET) and Myelofibrosis (MF) – Available forPreclinical Studies? Background. Researchers at the University of Cambridge have generated fully characterised,conditional knock-in mouse models for essential

1 Jul 2024: Ortho-quinone prodrug strategy (self-immolativelinkers). BACKGROUND. The para-quinones doxorubicin (Adriamycin),geldanamycin, mitoxantrone and mitomycin C have lowerredox-cycling rates than ortho-quinones and aresuccessfully used in the clinic.

1 Jul 2024: Implantable drug delivery device targeting braintumours. BACKGROUND. Successful treatment of brain cancers is limited due to the difficulty of deliveringtherapies to difficult-to-access tumours. There is also a need for new technologiesable to